Table 3.
Subgroup analysis of ChAd vs BNT demographics and outcomes. BNT patients were younger, but this was expected because the vaccination policy median age was 35 vs 68 (P <.001).
| ChAd | BNT | OR (95% CI) | P | |
|---|---|---|---|---|
| Demographics | ||||
| Male | 20 | 2 | 4.0 (0.74-20) | .15 |
| Female | 20 | 8 | ||
| De novo | 33 | 4 | 7.1 (1.7-26) | .01 |
| Prior ITP | 7 | 6 | ||
| First dose | 36 | 6 | 6.0 (1.4-26) | .04 |
| Second dose | 4 | 4 | ||
| Time from vaccination to presentation, median, d [IQR] | 17.0 [10.0–25.25] | 7.5 [2.0–19.25] | (Mann–Whitney U-test) | .11 |
| Outcomes | ||||
| WHO bleeding 0–1 | 26 | 9 | 0.21 (0.018 to 1.3) | .25 |
| WHO bleeding ≥2 | 14 | 1 | ||
| Need for second-line therapy | 16 | 1 | 6.0 (0.95 to 69) | .13 |
| No need for second-line therapy | 24 | 9 | ||
| On treatment at day 90 | 12 | 4 | 0.56 (0.13 to 2.5) | .68 |
| Off treatment at day 90 | 16 | 3 |
ITP, immune thrombocytopenia.